Advanced search
Publication Cover
Pharmacogenomics Volume 14, 2013 - Issue 13
Submit an article Journal homepage
575
Views
0
CrossRef citations to date
0
Altmetric
Special Report

Pharmacogenetics of Antiplatelets and Anticoagulants: A Report on Clopidogrel, Warfarin and Dabigatran

Stephanie Ross1 Population Health Research Institute, McMaster University, Hamilton General Hospital Campus, DB-CVSRI, 237 Barton Street East, Room C3103, Hamilton, ONL8L 2X2, CanadaView further author information
&
Guillaume Paré1 Population Health Research Institute, McMaster University, Hamilton General Hospital Campus, DB-CVSRI, 237 Barton Street East, Room C3103, Hamilton, ONL8L 2X2, Canada;3 Department of Clinical Epidemiology & Biostatistics, Population Genomics Program, McMaster University, Hamilton, ON, Canada;4 Thrombosis & Atherosclerosis Research Institute, Hamilton Health Sciences & McMaster University, Hamilton, ON, Canada;2 Department of Pathology & Molecular Medicine, McMaster University, Hamilton, ON, Canada.Correspondence[email protected]
View further author information
Pages 1565-1572 | Published online: 02 Oct 2013

References

  • Ahmad T , VooraD, BeckerRC. The pharmacogenetics of antiplatelet agents: towards personalized therapy? Nat. Rev. Cardiol.8 , 560–571 (2011).
  • Wells QS , DelaneyJT, RodenDM. Genetic determinants of response to cardiovascular drugs. Curr. Opin. Cardiol.27 , 253–261 (2012).
  • Verschuren JJ , JukemaJW. Pharmacogenetics of antiplatelet therapy: ready for clinical application? Heart97 , 1268–1276 (2011).
  • Yusuf S , ZhaoF, MehtaSR et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345(7) , 494–502 (2001).
  • Sibbing D , GebhardD, KochW et al. Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy. J. Thromb. Haemost. 8(8) , 1685–1693 (2010).
  • Frere C , CuissetT, GaboritB, AlessiMC, HulotJS. The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome. J. Thromb. Haemost.7 , 1409–1411 (2009).
  • Paré G , MehtaSR, YusufS et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N. Engl. J. Med. 363(18) , 1704–1714 (2010).
  • Sibbing D , KochW, GebhardD et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 121(4) , 512–518 (2010).
  • Wallentin L , JamesS, StoreyRF et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 376(9749) , 1320–1328 (2010).
  • Shuldiner AR , O‘ConnellJR, BlidenKP et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302(8) , 849–857 (2009).
  • Tantry US , BlidenKP, WeiC et al. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. Circ. Cardiovasc. Genet. 3(6) , 556–566 (2010).
  • Bhatt DL , ParéG, EikelboomJW et al. The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. Eur. Heart J. 33(17) , 2143–2150 (2012).
  • Mega JL , SimonT, ColletJP et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 304(16) , 1821–1830 (2010).
  • Mega JL , CloseSL, WiviottSD et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360 , 354–362 (2009).
  • Mega JL , CloseSL, WiviottSD et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 119(19) , 2553–2560 (2009).
  • Grosdidier C , QuiliciJ, LoosveldM et al. Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications. Am. J. Cardiol. 111(7) , 985–990 (2013).
  • Cuisset T , LoosveldM, MorangePE et al. CYP2C19*2 and *17 alleles have a significant impact on platelet response and bleeding risk in patients treated with prasugrel after acute coronary syndrome. JACC Cardiovasc. Interv.5(12) , 1280–1287 (2012).
  • Holmes MV , PerelP, ShahT, HingoraniAD, CasasJP. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA306 , 2704–2714 (2011).
  • Roberts JD , WellsGA, Le May MR et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet379(9827) , 1705–1711 (2012).
  • Price MJ , BergerPB, TeirsteinPS et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305(11) , 1097–1105 (2011).
  • Zabalza M , SubiranaI, SalaJ et al. Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. Heart 98(2) , 100–108 (2012).
  • Suh JW , KooBK, ZhangSY et al. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ 174(12) , 1715–1722 (2006).
  • Gladding P , WebsterM, ZengI et al. The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial. JACC Cardiovasc. Interv. 1(6) , 620–627 (2008).
  • Simon T , VerstuyftC, Mary-KrauseM et al. Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med. 360 , 363–375 (2009).
  • Brandt J , CloseJL, IturriaSJ et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J. Thromb. Haemost. 5(12) , 2429–2436 (2007).
  • Gros P , Ben Neriah YB, Croop JM, Housman DE. Isolation and expression of a complementary DNA that confers multidrug resistance. Nature323 , 728–731 (1986).
  • Taubert D , von Beckerath N, Grimberg G et al. Impact of P-glycoprotein on clopidogrel absorption. Clin. Pharmacol. Ther.80(5) , 486–501 (2006).
  • Mega JL , CloseSL, WiviottSD et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 376(9749) , 1312–1319 (2010).
  • Fontana P , DupontA, GandrilleS et al. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 108(8) , 989–995 (2003).
  • Cuisset T , FrereC, QuiliciJ et al. Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome. Thromb. Res. 120(6) , 893–899 (2007).
  • Giusti B , GoriAM, MarcucciR et al. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet. Genomics 17(12) , 1057–1064 (2007).
  • Wittkowsky AK . Warfarin and other coumarin derivatives: pharmacokinetics, pharmacodynamics, and drug interactions. Semin. Vasc. Med.3 , 221–230 (2003).
  • Hirsh J , FusterV, AnsellJ, HalperinJL. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J. Am. Coll. Cardiol.41 , 1633–1652 (2003).
  • D‘Andrea G , D‘AmbrosioRL, Di Perna P et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood105(2) , 645–649 (2005).
  • Rieder MJ , ReinerAP, GageBF et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352(22) , 2285–2293 (2005).
  • Wadelius M , ChenLY, DownesK et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J. 5(4) , 262–270 (2005).
  • Takeuchi F , McGinnisR, BourgeoisS et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 5 , e1000433 (2009).
  • Caldwell MD , AwadT, JohnsonJA et al. CYP4F2 genetic variant alters required warfarin dose. Blood111(8) , 4106–4112 (2008).
  • McDonald MG , RiederMJ, NakanoM, HsiaCK, RettieAE. CYP4F2 is a vitamin K1 oxidase: an explanation for altered warfarin dose in carriers of the V433M variant. Mol. Pharmacol.75 , 1337–1346 (2009).
  • Avery PJ , JorgensenA, HambergAK et al. A proposal for an individualized pharmacogenetics-based warfarin initiation dose regimen for patients commencing anticoagulation therapy. Clin. Pharmacol. Ther. 90(5) , 701–706 (2011).
  • Linder MW , Bon Homme M, Reynolds KK et al. Interactive modeling for ongoing utility of pharmacogenetic diagnostic testing: application for warfarin therapy. Clin. Chem.55(10) , 1861–1868 (2009).
  • Higashi MK , VeenstraDL, DondoLM et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287 , 1690–1698 (2002).
  • Aithal GP , DayCP, KestevenPJ, DalyAK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet353 , 717–719 (1999).
  • Limdi NA , McGwinG, GoldsteinJA et al. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African–American and European–American patients on warfarin. Clin. Pharmacol. Ther. 83(2) , 312–321 (2008).
  • Johnson JA , GongL, Whirl-CarrilloM et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin. Pharmacol. Ther. 90 , 625–629 (2011).
  • Watzka M , GeisenC, BevansCG et al. Thirteen novel VKORC1 mutations associated with oral anticoagulant resistance: insights into improved patient diagnosis and treatment. J. Thromb. Haemost. 9(1) , 109–118 (2011).
  • Manolopoulos VG , RagiaG, TavridouA. Pharmacogenetics of coumarinic oral anticoagulants. Pharmacogenomics11 , 493–496 (2010).
  • Eriksson N , WadeliusM. Prediction of warfarin dose: why, when and how? Pharmacogenomics13 , 429–440 (2012).
  • International Warfarin Pharmacogenetics Consortium; Klein TE, Altman RB, Eriksson N et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med.360 , 753–764 (2009).
  • van Schie RM , WadeliusMI, KamaliF et al. Genotype-guided dosing of coumarin derivatives: the European Pharmacogenetics of Anticoagulant Therapy (EU-PACT) trial design. Pharmacogenomics 10(10) , 1687–1695 (2009).
  • Lenzini P , WadeliusM, KimmelS et al. Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin. Pharmacol. Ther. 87(5) , 572–578 (2010).
  • Connolly SJ , EzekowitzMD, YusufS et al.; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med.361 , 1139–1151 (2009).
  • Ezekowitz MD , ConnollyS, ParekhA et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am. Heart J. 157(5) , 805–810 (2009).
  • Stangier J , RathgenK, StahleH, GansserD, RothW. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br. J. Clin. Pharmacol.64 , 292–303 (2007).
  • Liesenfeld KH , LehrT, DansirikulC et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J. Thromb. Haemost. 9(11) , 2168–2175 (2011).
  • Paré G , ErikssonN, LehrT et al. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation 127(13) , 1404–1412 (2013).
  • Wadkins RM , MortonCL, WeeksJK et al. Structural constraints affect the metabolism of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) by carboxylesterases. Mol. Pharmacol. 60(2) , 355–362 (2001).
  • Miller DS , BauerB, HartzAM. Modulation of P-glycoprotein at the blood–brain barrier: opportunities to improve central nervous system pharmacotherapy. Pharmacol. Rev.60 , 196–209 (2008).
  • Zhou S , LimLY, ChowbayB. Herbal modulation of P-glycoprotein. Drug Metab. Rev.36 , 57–104 (2004).
  • Stangier J , ClemensA. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin. Appl. Thromb. Hemost.15(Suppl. 1) , S9–S16 (2009).
  • Eikelboom JW , WallentinL, ConnollySJ et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial. Circulation 123 , 2363–2372 (2011).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.